share_log

BeyondSpring (NASDAQ:BYSI) Shares Up 0.7%

BeyondSpring (NASDAQ:BYSI) Shares Up 0.7%

万春医药(纳斯达克:BYSI)股价上涨0.7%
Financial News Live ·  2022/08/10 18:31

BeyondSpring Inc. (NASDAQ:BYSI – Get Rating)'s share price shot up 0.7% during trading on Monday . The stock traded as high as $1.57 and last traded at $1.52. 165,615 shares traded hands during trading, a decline of 59% from the average session volume of 403,071 shares. The stock had previously closed at $1.51.

纳斯达克周一盘中股价飙升0.7%,盘中一度涨至1.57美元,最新报1.52美元。当日有165,615股股票易手,较403,071股的日均成交量下跌59%。此前该股收盘价为1.51美元。

BeyondSpring Stock Performance

万春医药股票表现

The company has a market capitalization of $57.23 million, a PE ratio of -0.88 and a beta of 1.04. The firm has a fifty day moving average of $1.52 and a two-hundred day moving average of $1.94.

该公司市值为5723万美元,市盈率为-0.88,贝塔系数为1.04。该公司的50日移动均线切入位在1.52美元,200日移动均线切入位在1.94美元。

Get
到达
BeyondSpring
万春医药
alerts:
警报:

Institutional Investors Weigh In On BeyondSpring

机构投资者在万春医药上发表看法

Several institutional investors have recently bought and sold shares of BYSI. Walleye Capital LLC purchased a new stake in BeyondSpring during the 1st quarter valued at about $28,000. Mirabella Financial Services LLP purchased a new stake in BeyondSpring during the 1st quarter valued at about $44,000. Orion Portfolio Solutions LLC purchased a new stake in BeyondSpring during the 2nd quarter valued at about $44,000. Fox Run Management L.L.C. purchased a new stake in BeyondSpring during the 4th quarter valued at about $56,000. Finally, Acadian Asset Management LLC purchased a new stake in BeyondSpring during the 1st quarter valued at about $76,000. 18.89% of the stock is currently owned by hedge funds and other institutional investors.

几家机构投资者最近买卖了比亚迪的股票。Walleye Capital LLC在第一季度购买了万春医药的新股份,价值约28,000美元。米拉贝拉金融服务有限责任公司在第一季度购买了万春医药的新股份,价值约44,000美元。猎户座投资组合解决方案有限责任公司在第二季度购买了万春医药的新股份,价值约44,000美元。狐狸奔跑管理有限公司在第四季度购买了万春医药的新股份,价值约56,000美元。最后,阿卡迪亚资产管理有限责任公司在第一季度购买了万春医药的新股份,价值约76,000美元。18.89%的股票目前由对冲基金和其他机构投资者持有。

About BeyondSpring

关于万春医药

(Get Rating)
(获取评级)

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.

万春医药是一家临床期生物制药公司,与其子公司一起专注于癌症疗法的开发。该公司的主要资产是普利布林,这是一种选择性免疫调节微管结合剂,已经完成了预防化疗引起的中性粒细胞减少症和治疗晚期非小细胞肺癌的第三阶段临床试验。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on BeyondSpring (BYSI)
  • The How And Why of Investing in Oil Stocks
  • The How and Why of Investing in Gold Stocks
  • A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
  • Workhorse Group Is Ready To Get Back On The Horse
  • Are 3M, Honeywell, GE Buys After Quarterly Reports?
  • 在新浪万春医药上免费获取斯托克新闻网的研究报告
  • 投资石油股票的方式和原因
  • 投资黄金股票的方式和原因
  • DraftKings,Inc.的圆底开始逆转
  • 工作马集团准备重返赛马
  • 3M、霍尼韦尔、通用电气在季度报告后收购吗?

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.

接受万春医药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对万春医药及相关公司评级的每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发